Shilpa Medicare has launched Sunitinib Capsules, under the brand name ‘SUNISHIL’. Three strengths of Sunitinib capsules 12. 5 mg, 25 mg and 50 mg is launched at an attractive price for the benefit of patients. Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities.
Sunitinib Capsules are indicated for the treatment of G.I. Stromal tumor after disease progression on or intolerance to Imatinib mesylate, advanced Renal Cell Carcinoma, and for the treatment of Unresectable or Metastatic Well-differentiated Pancreatic Neuroendocrine Tumors with Disease Progression in Adults.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
